

NUCLEAR MEDICINE UPDATE 2010
Conjoint Meeting of LARS Nuclear Medicine Section &
Pacific Southwest Chapter Society of Nuclear Medicine
MARCH 27, 2010 – HILTON PASADENA

SESSION I - MULTI MODALITY IMAGING OF DISEASE (PET/SPECT/CT)

8:00–8:30am

New Developments in PET/CT Imaging of Myocardial Perfusion and Comparison to SPECT (CA Scope: .5 I)

– Jamshid Maddahi, MD, FACC

Upon completion of this lecture, participants will be able to

- Describe the current limitations of SPECT and PET in evaluation of myocardial perfusion and coronary artery disease.
- Summarize the potential advantages of a new F-18 labeled myocardial perfusion PET tracer in evaluation of coronary artery disease.

8:30–9:00am

PET Power in Oncology (CA Scope: .5 I) – Lalitha Ramanna, MD

Upon completion of this lecture, participants will be able to

- List Medicare approved indications for PET/CT imaging
- Outline the role of PET/CT imaging in some oncological applications
- Describe the advantages of PET/CT when compared to conventional imaging.

9:00– 9:30am

Infection (CA Scope: .5 I) – Alan D. Waxman, MD

Upon completion of this lecture, participants will be able to

- Outline the molecular imaging methods for detection of infection
- Apply the optimal approach to detection of specific infections.

9:30– 10:00am

Edwin C. Glass, MD

Molecular Imaging in Endocrinology (CA Scope: .5 I or RTBD) –

Upon completion of this lecture, participants will be able to

- Describe at least 3 uptake mechanisms now used to image endocrine tumors
- List two tumor types that are usually well depicted using In-111 Octreotide
- List two tumor types that are usually well depicted using F-18 DOPA

10:00– 10:30am BREAK - Visit Exhibitors

SESSION II - FRONTIERS OF MOLECULAR IMAGING

10:30-11:00am

Stem Cell Primer (CA Scope: NI) – Cameron Foster, MD

Upon completion of this lecture, participants will be able to

- Identify what differentiates a normal cell from a stem cell
Identify sources of stem cells
- Demonstrate how nuclear medicine integrates with stem cell trafficking

11:00-11:30am

Molecular Biology Correlates of Tumor FDG Uptake (CA Scope: .5 R)

– Hossein Jadvar, MD, PhD, MPH, MBA

Scientific Program Chairman

Upon completion of this lecture, participants will be able to

- Outline the molecular biology determinants of FDG uptake in tumors
- Describe the correlation of the level and extent FDG uptake to lung, breast, and colon cancer biology.

11:30-12:00pm

Roundtable Discussion - Session I & II Faculty (CA Scope: .5 I)

Upon completion of this session participants will be able to

Evaluate multimodality imaging and molecular imaging

12:00 – 1:00pm

LUNCH

NUCLEAR MEDICINE UPDATE 2010
Conjoint Meeting of LARS Nuclear Medicine Section &
Pacific Southwest Chapter Society of Nuclear Medicine
MARCH 27, 2010 – HILTON PASADENA

SESSION III - SURVIVAL KIT: FACING REALITY

- 1:00-1:30pm** **Accreditation 2012 and Your Imaging Laboratory (CA Scope: .5 NI)**
– **Brenda J. King, CNMT, SNMTS**
Upon completion of this lecture, participants will be able to
- List the CMS (MIPPA 2008) requirements for imaging laboratories accreditation
 - Avoid stumbling blocks in the accreditation process
- 1:30-2:00pm** **Coping with Reimbursement Trends (CA Scope: .5 NI)**
– **Dominique Delbeke, MD, PhD**
Upon completion of this lecture, participants will be able to
- Discuss the SNM mission and accomplishments for 2009
 - Discuss the challenges related to reimbursement proposals by the healthcare reform
 - Discuss the efforts from SNM to help membership regarding reimbursement issues
- 2:00-2:30pm** **Reducing Radiation Exposure from Medical Imaging (CA Scope: .5 R)**
– **Patrick M. Colletti, MD**
Upon completion of this lecture, participants will:
- Recognize deterministic and stochastic radiation risks
 - Identify systematic opportunities to reduce patient radiation exposure associated with medical imaging
- 2:30-3:00pm** **BREAK - Visit Exhibitors**

SESSION IV - THERAPY

- 3:00-3:30pm** **Radioimmunotherapy for Treatment of Lymphoma:**
Best Practices (CA Scope: .5 T) – Peter S. Conti, MD, PhD
Upon completion of this lecture, participants will be able to
- Recognize the role of Radioimmunotherapy in the treatment of Lymphoma
 - Apply the best practice approaches to delivery of RIT
- 3:30-4:00pm** **PET/CT in Radiation Treatment Planning: Application of Biologic**
Target Volumes (CA Scope: .5 I) – Sherief H. Gamie, MD, PhD
Upon completion of this lecture, participants will be able to outline the
- Application of biologic target volumes using PET/CT in external beam radiation therapy treatment planning
 - Application of peritumoral target volumes using PET/CT in brachytherapy
- 4:00-4:30pm** **PET/CT in Monitoring Treatment Response (CA Scope: .5 I)**
– **Johannes Czernin, MD**
Upon completion of this lecture, participants will be able to
- Describe the concept of replacing size based RECIST by PET based response criteria
 - Suggest timing of response assessments with PET/CT
 - Outline SUV criteria for defining response versus non-response
- 4:30-5:00pm** **Roundtable Discussion - Session III & IV Faculty (CA Scope: .5 NI)**
This session will provide a forum for discussion among speakers and the audience.
Upon completion of this session:
- Attendees will be able to identify different aspects of accreditation, reimbursement, radiation exposure and therapy.